NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









QL Biopharm

QL Biopharm

Private
BeijingHealthcare & Life Scienceshttps://qlbiopharm.com/

Last Round

Series C

Mar 2, 2026

Est. Valuation

$417.5M

Total Funding Raised

$158.5M

Company Overview

QL Biopharm is a biotechnology company that develops innovative drugs for chronic metabolic diseases such as obesity, diabetes, and non-alcoholic fatty liver disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

GLP-1 receptor agonistobesity treatmentrecombinant proteinweight loss drugtype 2 diabetesMASHpeptide therapeuticsdrug discoveryGMP manufacturingbiopharmaceuticalmetabolic diseasepharmaceutical intermediatesonce-monthly injectionbiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

QL Biopharm Comps

Public and private peers based on sector, stage, and business model.

QL Biopharm comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

QL Biopharm Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMar 2, 2026
Series CFeb 17, 2025
Series B ExtensionNov 27, 2023
Series BMar 6, 2023
Series BFeb 15, 2022
Series A
Oct 27, 2020

QL Biopharm Investors

Notable investors and investment history

QL Biopharm investors
InvestorRounds
Lanchi VenturesSeries B Extension, Series B
BioTrack CapitalSeries A
TF CapitalSeries C
Jiyuan CapitalSeries B Extension
Tigeryeah CapitalSeries C, Series A
OrbiMedSeries C
中国风险投资有限公司Series C

QL Biopharm Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

QL Biopharm Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about QL Biopharm's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Year Founded2018
Last FundingMar 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.